Phase 3
Completed

Anifrolumab (Saphnelo)

Sponsored by AstraZeneca
Timeline
Study Dates
Start Date
January 2022
Est. Completion
December 2025
Enrollment Target
200 participants
Status
Completed
Study Design
Primary Endpoint
Efficacy and safety of subcutaneous anifrolumab administration compared to intravenous formulation
⚠ No ClinicalTrials.gov registry ID found for this program. This trial was announced but no registered study has been identified. CelluTarget flags this distinction rather than treating announced and registered trials as equivalent.
Related Treatment
Treatment Being Studied
Anifrolumab (Saphnelo)